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Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts
Due to Enhanced Na+–Glucose Cotransport
Rebekah Lambert, MS; Sarah Srodulski, BS; Xiaoli Peng, BS; Kenneth B. Margulies, MD; Florin Despa, PhD; Sanda Despa, PhD

Background-—Intracellular Na+ concentration ([Na+]i) regulates Ca2+ cycling, contractility, metabolism, and electrical stability of
the heart. [Na+]i is elevated in heart failure, leading to arrhythmias and oxidative stress. We hypothesized that myocyte [Na+]i is
also increased in type 2 diabetes (T2D) due to enhanced activity of the Na+–glucose cotransporter.
Methods and Results-—To test this hypothesis, we used myocardial tissue from humans with T2D and a rat model of late-onset
T2D (HIP rat). Western blot analysis showed increased Na+–glucose cotransporter expression in failing hearts from T2D patients
compared with nondiabetic persons (by 7313%) and in HIP rat hearts versus wild-type (WT) littermates (by 618%). [Na+]i was
elevated in HIP rat myocytes both at rest (14.70.9 versus 11.40.7 mmol/L in WT) and during electrical stimulation (17.30.8
versus 15.00.7 mmol/L); however, the Na+/K+-pump function was similar in HIP and WT cells, suggesting that higher [Na+]i is
due to enhanced Na+ entry in diabetic hearts. Indeed, Na+ inﬂux was signiﬁcantly larger in myocytes from HIP versus WT rats
(1.770.11 versus 1.290.06 mmol/L per minute). Na+–glucose cotransporter inhibition with phlorizin or glucose-free solution
greatly reduced Na+ inﬂux in HIP myocytes (to 1.200.16 mmol/L per minute), whereas it had no effect in WT cells. Phlorizin also
signiﬁcantly decreased glucose uptake in HIP myocytes (by 339%) but not in WT, indicating an increased reliance on the Na+–
glucose cotransporter for glucose uptake in T2D hearts.
Conclusions-—Myocyte Na+–glucose cotransport is enhanced in T2D, which increases Na+ inﬂux and causes Na+ overload. Higher
[Na+]i may contribute to arrhythmogenesis and oxidative stress in diabetic hearts. ( J Am Heart Assoc. 2015;4:e002183 doi:
10.1161/JAHA.115.002183)
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T

ype 2 diabetes (T2D) heightens the risk of developing
heart failure (HF), arrhythmias, and sudden cardiac
death, even in the absence of vascular complications such as
coronary artery disease and hypertension.1–5 Severe heart
dysfunction often occurs before full-blown diabetes is diagnosed (prediabetes),6–9 suggesting an early and critical
maladaptation of myocardial structure and function. The
mechanisms that link T2D to the electrical and structural
remodeling of the myocardium are multifactorial but poorly
understood.
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In the heart, intracellular Na+ concentration ([Na+]i) and
Na+ transport are critical modulators of Ca2+ cycling,
contractility, energy supply and demand, oxidative state,
action potential waveform, and propensity for arrhythmias.10
[Na+]i is elevated in HF,11–15 which mitigates contractile
dysfunction by favoring more Ca2+ inﬂux via the Na+/Ca2+
exchanger (NCX), thus augmenting the cellular and sarcoplasmic reticulum Ca2+ load; however, increased sarcoplasmic
reticulum Ca2+ load also raises the risk for arrhythmias.16 At
the same time, high [Na+]i induces oxidative stress by
activating the mitochondrial NCX, leading to lower free Ca2+
in the mitochondria and slower regeneration of NADPH, which
is needed to neutralize the reactive oxygen species produced
in the mitochondria.17–19 Both decreased Na+ extrusion and
increased Na+ entry may contribute to the rise in [Na+]i in HF,
depending on the etiology of the disease.
Few studies have so far investigated myocardial Na+
transport in diabetes. Decreased activity of the Na+/K+
pump20,21 (NKA) and NCX22,23 were reported in hearts from
animals with type 1 diabetes. The myocardial Na+/H+
exchanger was found to be enhanced in hearts from
T2D animals,24,25 which contributed to left ventricular
Journal of the American Heart Association
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Methods
Experimental Animals
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85–23, revised 1996) and was
approved by the institutional animal care and use committee
at the University of Kentucky. The T2D animal model used in
this study is the HIP rat. HIP rats are obese Sprague-Dawley
rats that express human amylin, an amyloidogenic hormone
cosecreted with insulin, in the pancreatic b cells on the insulin
II promoter.31 Increased amylin secretion in the insulinresistant prediabetic state causes its aggregation and deposition in pancreas in both humans31 and HIP rats,32 which
leads to gradual decline of b-cell mass and development of full
T2D.31–33 Because rodent amylin is not amyloidogenic, HIP
rats are unique within rodent T2D models in showing amylin
amyloid deposition. Together with the late-onset development
of T2D, this characteristic makes the HIP rat a “humanized”
T2D animal model. We recently demonstrated that amylin
accumulation in humans with obesity or T2D and in HIP rats is
not limited to the pancreas but also occurs in peripheral
DOI: 10.1161/JAHA.115.002183

organs, including the heart.34,35 HIP rats were monitored
biweekly for nonfasting blood glucose (with a glucometer) and
used in experiments when glucose was >400 mg/dL
(22.5 mmol/L) for >8 consecutive weeks (ie, late-stage
T2D). Age-matched wild-type (WT) littermates were used as
nondiabetic controls. Because the genetic background of HIP
rats is the Sprague-Dawley rat, the WT animals are also obese.
In fact, the body weight of the WT rats (69820 g) was larger
than that of HIP rats (61125 g) at the time they were used
for experiments, due to weight loss in HIP rats after
development of full-blown diabetes. Sample sizes of 20
diabetic male HIP rats and 20 WT male rats were used in this
study.

Human Samples
Human left ventricular tissue was from hearts obtained at the
time of orthotopic heart transplantation at the Hospital of the
University of Pennsylvania (for failing hearts) or organ
donation (for nonfailing hearts), in accordance with institutional review board approval and after obtaining informed
consent. The hearts were divided into 5 pathological groups,
depending on the presence of T2D and HF and body weight.
The average age and body mass index, sex distribution, and
HF etiology (ischemic versus nonischemic) of the patients in
the 5 groups are shown in Table. The ﬁrst group is that of
hearts from patients with both T2D and HF (T2D-HF group; 4
hearts). T2D in these patients was controlled with either
insulin (for 2 cases) or oral glucose-lowering drugs (n=2).
Failing hearts from non-T2D patients were divided into the
failing-obese (OB-HF; n=6) and failing-lean (L-HF; n=7) groups
based on the body mass index of the patient (≥30 kg/cm2 for
the obese group; <30 kg/cm2 for lean). Nonfailing hearts
were also divided into OB-NF (n=6) and L-NF (n=6) groups.
Table. Average Age and BMI (SD), Sex Distribution, and HF
Etiology (Ischemic Versus Nonischemic) of the Patients
Whose Hearts Were Used in this Study
Group

Age

BMI (kg/cm2)

Sex

HF Etiology

T2D-HF

568

32.61.5

All male

3 ischemic,
1 dilated

OB-HF

5112

33.53.7

5 male,
1 female

2 ischemic,
4 dilated

L-HF

539

21.82.0

4 male,
3 female

5 dilated,
2 hypertrophic

OB-NF

5513

33.02.3

4 male,
2 female

NA

L-NF

6118

25.51.8

3 male,
3 female

NA

BMI indicates body mass index; HF, heart failure; L, lean; NA, not available; NF, nonfailing
heart; OB, obese; T2D, type 2 diabetes.
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hypertrophy24 and led to higher [Na+]i gain during ischemia–
reperfusion.25 Na+/H+ exchanger inhibition was associated
with a lower incidence of ventricular tachycardia and ﬁbrillation in T2D hearts during ischemia–reperfusion25; however, it
is currently unknown whether myocyte [Na+]i is altered in T2D
and how such alterations affect the progression of diabetic
heart disease.
We hypothesized that [Na+]i is elevated in diabetic hearts
due to enhanced Na+ entry through the Na+–glucose
cotransporter (SGLT), which couples the uptake of Na+ ions
and glucose. SGLT is present in the heart,26,27 but its
physiological and pathophysiological roles are not fully
understood. Recent data demonstrated that cardiac-speciﬁc
overexpression of the SGLT1 isoform causes hypertrophy and
left ventricular dysfunction.28 The mRNA level of cardiac
SGLT1 is increased in HF and T2D,27 2 pathological conditions
that render the heart insulin resistant. SGLT1 seems to be
required for activation of NADPH oxidase by hyperglycemia.29
Moreover, SGLT-mediated glucose uptake has been linked to
PRKAG2 cardiomyopathy,30 a glycogen storage cardiomyopathy caused by mutations in the gene encoding the c2 subunit
of AMP-activated protein kinase. The activity of cardiac SGLT
may be increased in T2D as an adaptation to both chronic
hyperglycemia and the reduced ability of myocytes to take up
glucose through insulin-dependent pathways. We tested this
hypothesis by analyzing [Na+]i and SGLT expression and
function in hearts from rats and humans with T2D versus
nondiabetic controls.

[Na+]i, Na+–Glucose Cotransport in Diabetic Hearts

Lambert et al

Left ventricular tissue was homogenized in homogenization
buffer containing 10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L
NaCl, 0.1% sodium dodecyl sulfate, 1% Triton X-100, 1%
sodium deoxycholate, 5 mmol/L EDTA, 1 mmol/L NaF,
1 mmol/L sodium orthovanadate, and protease and phosphatase inhibitor cocktail (Calbiochem). After SDS-PAGE
electrophoresis, proteins were transferred on nitrocellulose
membranes, blocked, and probed with primary antibodies
against SGLT1 (Santa Cruz Biotechnology) and the a1
(Millipore) and a2 (Millipore) isoforms of the Na+/K+-ATPase.
Equal loading was veriﬁed by reprobing with anti-GAPDH
(Abcam). Signal intensity analysis was performed in ImageJ
(National Institutes of Health). For each gel, we averaged the
signal intensity of the corresponding bands for the control
samples. We then normalized the signal intensity in all lanes
to this average. This procedure was repeated on at least 4
gels, and for each sample, the normalized signal intensity was
averaged. In the end, we calculated averages over all groups
used.

Immunoﬂuorescence
Freshly isolated myocytes were plated on laminin-coated
coverslips, ﬁxed with 4% paraformaldehyde, permeabilized
with 50 lg/mL saponin (15 minutes), blocked with 2% goat
serum, and labeled with a polyclonal primary antibody against
SGLT1 (Santa Cruz Biotechnology). Anti-rabbit Alexa Fluor 488
was used as a secondary antibody, and ﬂuorescence images
were collected with a laser scanning confocal microscope.

strophanthidin. With our experimental setup, the SBFI ratio
increased linearly with [Na+]i up to 50 mmol/L.
To measure NKA function in intact myocytes, cells were
Na+ loaded by blocking the pump in K+-free solution. [Na+]i
decline was measured in Na+-free solution, differentiated,
plotted as a function of [Na+]i, and ﬁtted with the Hill
equation.11 Such measurements were done in the absence
and presence of 10 mmol/L ouabain in the Na+-free solution.
In the ﬁrst case, Na+ efﬂux was mediated by both NKA and
passive leak, whereas in the second case, the only contribution was that of the passive Na+ leak.
Resting Na+ inﬂux was taken as the initial rate of [Na+]i rise
following abrupt NKA inhibition with 10 mmol/L ouabain.

Glucose Uptake Measurements
Myocyte glucose uptake was measured using the ﬂuorescent
glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)2-deoxyglucose, or 2-NBDG (Life Technologies).36,37 Myocytes
were preincubated in glucose-free Tyrode’s solution for
60 minutes, and then they were incubated with 1 mmol/L
2-NBDG for 30 minutes in the absence or presence of
250 lmol/L phlorizin or 50 nmol/L insulin. External 2-NBDG
was washed off, and the cells were imaged with a confocal
microscope using identical settings for all measurements. For
each rat, we calculated the mean ﬂuorescence intensity per
group (a minimum of 20 cells per group), and we normalized
the ﬂuorescence in the phlorizin and insulin groups to the
control. Measurements were repeated in cells from 6 HIP and
6 WT rats.

Cardiac Myocyte Isolation

Statistical Analysis

Rats were anesthetized with 3% to 5% isoﬂurane (100% O2),
then hearts were excised quickly, placed on a gravity-driven
Langendorff perfusion apparatus, and perfused with 1 mg/
mL collagenase. When the heart became ﬂaccid (15 minutes), the left ventricular tissue was cut into small pieces,
dispersed, and ﬁltered, and the myocyte suspension was
rinsed several times. The standard Tyrode’s solution used in
experiments with live myocytes contained (in mmol/L) 140
NaCl, 4 KCl, 1 MgCl2, 10 glucose, 5 HEPES, and 1 CaCl2 (pH
7.4). All experiments were done at room temperature (23°C
to 25°C).

The data are presented as meanSE. For data that passed the
D’Agostino and Pearson normality test, statistical discriminations were performed using a 2-tailed unpaired Student t test
when comparing 2 groups and 1-way ANOVA with Bonferroni’s post hoc test when comparing multiple groups. When
the sample size was too small to perform the normality test,
data were analyzed with nonparametric tests (Mann–Whitney
when comparing 2 columns, Kruskal–Wallis followed by
Dunn’s post test when comparing multiple columns).
Differences were considered statistically signiﬁcant when
P<0.05.

[Na+]i Measurements

Results

[Na+]i was measured using the ﬂuorescent indicator SBFI
(TefLabs), as described previously.11 The SBFI ratio was
calibrated at the end of each experiment using divalent-free
solutions with 0, 10, or 20 mmol/L of extracellular Na+ in the
presence of 10 lmol/L gramicidin and 100 lmol/L
DOI: 10.1161/JAHA.115.002183

Increased SGLT1 Protein Expression in Hearts
From Diabetic and Obese Humans and Rats
We started to test the hypothesis that Na+–glucose
cotransport is enhanced in T2D hearts by evaluating the
Journal of the American Heart Association
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[Na+]i, Na+–Glucose Cotransport in Diabetic Hearts
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Figure 1. Increased SGLT1 protein expression in hearts from humans and rats with T2D.
A, Western blots with an anti-SGLT1 antibody in homogenates of failing hearts from patients
with T2D (T2D-HF group; 4 hearts) or obese (OB-HF group; 6 hearts) vs lean participants (LHF group; 7 hearts). GAPDH was used as loading control, and experiments were repeated 4
times. Bar graph in the right panel shows the relative band intensity. B, SGLT1 expression in
homogenates from failing vs nonfailing human hearts from lean (top) and obese (bottom)
participants. C, Western blots with an anti-SGLT1 antibody in diabetic HIP vs WT heart
homogenates. D, Representative immunoﬂuorescence images of rat (WT and HIP) myocytes
labeled with an anti-SGLT1 antibody. In both cases, SGLT1 is localized at the T-tubules. HF
indicates heart failure; HIP, model of late-onset T2D; L, lean; NF, nonfailing heart; OB, obese;
SGLT, Na+-glucose cotransporter; T2D, type 2 diabetes; WT, wild-type. *P<0.05, **P<0.01.

effect of T2D on the protein expression of SGLT1 in human
hearts, using Western blots (Figure 1A). Because a previous
study reported an increased mRNA level of SGLT1 in HF,27
we compared failing hearts from T2D, obese (likely in an
insulin-resistant prediabetic state), and lean (metabolically
normal) patients. We found that SGLT1 expression was
DOI: 10.1161/JAHA.115.002183

upregulated (by 7313%) in hearts from patients with T2D
versus nondiabetic, lean participants (Figure 1A). Moreover,
SGLT1 expression was even increased in hearts from obese
patients who were not diagnosed with T2D (by 315%)
(Figure 1A). We also noted that the presence of HF alone
resulted in higher cardiac SGLT1 expression in both lean and
Journal of the American Heart Association

Downloaded from http://jaha.ahajournals.org/ at University of Kentucky--Lexington on February 16, 2016

4

Lambert et al

[Na+]i (mmol/L)

A 17

2 Hz

16
15
14
13
12

5 min

B 20

*

*

15
10
5
0

HIP

To determine whether the increase in SGLT expression in
diabetic hearts affects myocyte Na+ homeostasis, we measured [Na+]i in myocytes isolated from diabetic HIP and WT
littermate rats using the ﬂuorescent indicator SBFI (Figure 2).
After measuring the resting [Na+]i, myocytes were electrically
stimulated to contract at 2 Hz (Figure 2A). As in our previous
studies,11,38,39 [Na+]i increased when the myocytes started
to contract, reaching a new steady state within 5 to
8 minutes. [Na+]i was signiﬁcantly higher in both resting
(14.70.9 versus 11.40.7 mmol/L in WT) and contracting
(17.30.8 mmol/L versus 15.00.7 mmol/L) HIP rat myocytes compared with WT (Figure 2B). Consequently, [Na+]i is
elevated in diabetic hearts.

Higher [Na+]i in diabetic hearts could be caused by reduced Na+
extrusion through NKA or increased Na+ inﬂux (or a combination of both). To uncover the mechanisms responsible for
elevated [Na+]i in T2D, we assessed NKA function in myocytes
from HIP and WT rats (Figure 3). Intact myocytes were Na+
loaded by blocking NKA in K+-free solution (Figure 3A). NKA
was reactivated (by reintroducing external K+), and [Na+]i
decline was measured in an Na+-free external solution.
Because cell volume does not change in these conditions,11
[Na+]i decline reﬂects Na+ extrusion. The rate of Na+ extrusion
was then calculated as a function of [Na+]i by numerically
differentiating the [Na+]i decline. The decrease in [Na+]i was
mediated mainly by NKA, but there was also a small component
due to passive Na+ leak (because the normal transmembrane
Na+ gradient is now inverted). We separately measured this
Na+ leak in experiments in which [Na+]i decay occurred in the
presence of 10 mmol/L ouabain, which completely blocks
NKA (Figure 3A). The rate of NKA-mediated Na+ extrusion was
then calculated as the difference between the total rate of
[Na+]i decline and the rate of passive Na+ leak. As shown in
Figure 3B, there were no signiﬁcant differences between HIP
and WT myocytes at [Na+]i in the physiological range (0
to 20 mmol/L). The curves were ﬁtted with a Hill expression to derive the maximum NKA rate (6.60.6 versus
7.50.6 mmol/L per minute in HIP versus WT, respectively;
P=0.33), the apparent binding constant for internal Na+
(8.91.3 versus 12.11.2 mmol/L in HIP versus WT, respectively; P=0.11), and the Hill coefﬁcient (2.00.6 versus
2.20.5 in HIP versus WT, respectively; P=0.82).
In agreement with largely unaltered NKA function in
myocytes from diabetic rats versus control, Western blots

Ctl

Elevated [Na+]i in Myocytes From Diabetic Hearts

Unchanged NKA Function in Diabetic Hearts at
Physiological [Na+]i

Rest

2 Hz

Figure 2. [Na+]i is elevated in myocytes from diabetic HIP rats vs WT. A, Representative

example of [Na+]i measurements in a HIP rat myocyte. [Na+]i was ﬁrst measured at rest,
then cells were electrically stimulated at 2 Hz. B, Mean steady-state [Na+]i at rest and
during electrical stimulation in myocytes from HIP (9 cells from 5 rats) and WT rats (7
myocytes from 5 animals). Ctl indicates control; HIP, model of late-onset T2D; [Na+]i,
intracellular Na+ concentration; WT, wild-type. *P<0.05
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obese participants (Figure 1B), in agreement with prior
mRNA data.27
A comparable level of SGLT1 upregulation occurred in
hearts from diabetic HIP rats versus WT littermates (618%)
(Figure 1C). HIP rats develop late-onset T2D32,33 and, as we
previously showed, manifest a cardiac phenotype that
provides a good resemblance of the diabetic cardiomyopathy
in humans with T2D.34,35
To transport Na+ and glucose, SGLT has to be localized at
the membrane. We assessed the distribution of SGLT1 in
cardiac myocytes from HIP and WT rats by immunoﬂuorescent
labeling with an anti-SGLT1 antibody (Figure 1D). These
experiments showed that in both WT and HIP rat myocytes,
SGLT1 is positioned in a striated pattern with 2 lm between
the transverse striations, which strongly suggests localization
at the T-tubules. Consequently, SGLT1 is localized at the
sarcolemma, and its expression is elevated in hearts from
humans and rats with T2D.

[Na+]i (mmol/L)

[Na+]i, Na+–Glucose Cotransport in Diabetic Hearts
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A

NKA rate (mmol/L/min)

[Na+]i, Na+–Glucose Cotransport in Diabetic Hearts

NKA-α1

*

NKA-α2

Figure 3. Unchanged NKA function in myocytes from diabetic rats. A, Representative
example of Na+ extrusion measurements in 2 myocytes from HIP rats. Intact myocytes were
Na+ loaded by blocking NKA in K+ free solution, and then external K+ was reintroduced, and
[Na+]i decline was measured in the absence (Ctl) or presence (ouabain) of 10 mmol/L
ouabain. [Na+]i decline was then numerically differentiated to calculate the rate of Na+
extrusion. B, Rate of NKA-mediated Na+ extrusion as a function of [Na+]i in intact myocytes
from HIP and WT rats (9 cells from 5 HIP rats and 6 cells from 5 WT rats). C, Protein
expression of the a1 and a2 isoforms of the NKA in hearts from WT rats and HIP rats in the
prediabetic (HIP-PD; nonfasting blood glucose in the 150 to 200 mg/dL range) and fully
diabetic (HIP-DM; blood glucose >400 mg/dL for >8 consecutive weeks) groups. NKA
indicates Na+/K+ pump; HIP, model of late-onset T2D; [Na+]i, intracellular Na+ concentration; WT, wild-type. *P<0.05

showed little change in the expression of NKA-a isoforms
(Figure 3C). Indeed, NKA-a1 expression was similar in
myocytes from HIP (in the prediabetic and fully diabetic
states) and WT rats. The expression of the a2 subunit was
reduced signiﬁcantly (by 544%) in the fully diabetic HIP rats
(Figure 3C); however, NKA-a2 represents <25% of the total
NKA in rat myocytes.40,41 Consequently, a 50% reduction in
NKA-a2 means that total NKA expression is reduced by
12.5%, which has only a minor effect on total NKA function.
Nonetheless, several studies have demonstrated that NKA-a2
has a preferential role in regulating Ca2+ cycling and cardiac
hypertrophy.41–44 A reduction in NKA activity (local or global)
improves contractility; therefore, the selective downregulation
of NKA-a2 may be an adaptation meant to limit the decrease
in cardiac function in diabetic hearts, but lower NKA-a2 also
promotes arrhythmogenesis and hypertrophy.
In summary, these data indicate that NKA function is not
signiﬁcantly altered in HIP rat myocytes; therefore, elevated
[Na+]i must be due to increased Na+ inﬂux.
DOI: 10.1161/JAHA.115.002183

Enhanced Na+ Entry Through SGLT in Myocytes
From Diabetic Rats
We measured Na+ inﬂux in resting myocytes from control and
diabetic rats as the slope of the initial increase in [Na+]i on
blocking NKA with 10 mmol/L ouabain (Figure 4A and 4B).
As expected from the ﬁndings that [Na+]i is elevated and NKA
function is unchanged, Na+ inﬂux was signiﬁcantly larger
in HIP myocytes versus WT (1.770.11 versus
1.290.06 mmol/L per minute) (Figure 4B).
Multiple pathways mediate Na+ entry in cardiac myocytes.
To assess the contribution of SGLT to the excess Na+ entry in
myocytes from diabetic rats, we measured Na+ inﬂux with
SGLT blocked by a speciﬁc pharmacological inhibitor
(phlorizin, 250 lmol/L) or by omission of glucose from the
external solution (Figure 4A and 4C). SGLT inhibition through
either method had no effect on WT myocytes but signiﬁcantly
reduced Na+ entry in myocytes from diabetic rats (to
1.200.16 and 1.090.16 mmol/L per minute for phlorizin
Journal of the American Heart Association
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Figure 4. Na+ inﬂux in myocytes from control and diabetic rats. A, Representative
example of Na+ inﬂux measurements in resting HIP rat myocytes in the absence (Ctl) and
presence of the SGLT inhibitor phlorizin (250 lmol/L). B, Na+ inﬂux calculated as the slope
of the initial increase in [Na+]i on blocking the Na+/K+ pump with 10 mmol/L ouabain in
myocytes from HIP and WT rats. C, Effect of SGLT inhibition with phlorizin and glucose-free
external solution on the rate of Na+ entry in myocytes from WT and diabetic HIP rats. D,
SGLT-mediated Na+ inﬂux derived by subtracting the rate of Na+ entry with SGLT blocked
from the total Na+ inﬂux. Mean of >7 cells from at least 5 rats in each group. HIP indicates
model of late-onset T2D; [Na+]i, intracellular Na+ concentration; SGLT, Na+–glucose
cotransporter; WT, wild-type. *P<0.05, **P<0.01
and glucose-free solution, respectively) (Figure 4C). In fact,
with SGLT blocked, Na+ inﬂux was similar in WT and HIP
myocytes. The SGLT-mediated Na+ entry, calculated by
subtracting the Na+ inﬂux with SGLT blocked from the total
rate of Na+ entry, was greatly increased in HIP versus WT
myocytes (Figure 4D). Consequently, SGLT activity is augmented in diabetic hearts, in which it becomes an important
factor in regulating [Na+]i.

and in the presence of 50 nmol/L insulin (Figure 5). As
expected, insulin signiﬁcantly enhanced glucose uptake in
myocytes from WT rats (by 4312%), whereas phlorizin
yielded no signiﬁcant effect (Figure 5A and 5B). In contrast,
insulin produced only a small (not signiﬁcant) effect in
myocytes from T2D rats, but SGLT inhibition greatly reduced
the glucose uptake (by 339%) (Figure 5A and 5C). These
results suggest that diabetic hearts rely more heavily on SGLT
for taking up glucose, possibly as a maladaptation to insulin
resistance.

Increased SGLT-Mediated Glucose Uptake in
Myocytes From Diabetic Rats
To further investigate SGLT function in myocytes from
diabetic and control rats, we measured glucose uptake using
a ﬂuorescent glucose analog, 2-NBDG (Figure 5).36,37 2-NBDG
is taken up into cells through both Glut transporters45,46 and
SGLT.47,48 Glucose uptake was measured under control
conditions, with SGLT blocked by 250 lmol/L phlorizin,
DOI: 10.1161/JAHA.115.002183

Discussion
We found increased SGLT expression in failing hearts from
T2D patients compared with those of nondiabetic participants
and in diabetic HIP versus WT rat hearts. HIP rat myocytes
exhibited enhanced SGLT-mediated Na+ (and glucose) uptake,
which resulted in higher [Na+]i.
Journal of the American Heart Association
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Figure 5. Increased SGLT-mediated glucose uptake in myocytes from diabetic rats. Glucose uptake was measured using the
ﬂuorescent glucose analog 2-NBDG. A, Representative ﬂuorescent
images of myocytes incubated with 1 mmol/L 2-NBDG for
30 minutes under control conditions (Ctl), with SGLT blocked by
250 lmol/L phlorizin and in the presence of 50 nmol/L insulin. B
and C, Mean ﬂuorescence intensity (relative to the control
condition) in myocytes from WT rats (B) and diabetic HIP rats (C);
n=6 rats, ≥20 cells/rat for both WT and HIP. HIP indicates model
of late-onset T2D; SGLT, Na+–glucose cotransporter; WT, wildtype. *P<0.05

Altered Myocyte Na+ Homeostasis in Diabetic
Hearts
There are few reports of altered cardiac Na+ transport in
diabetic animal models (mostly type 1 diabetes)20–25; however, it is currently unclear whether myocyte Na+ homeostasis
is perturbed in T2D. We found that [Na+]i was elevated in
myocytes from rats with late-onset T2D (HIP rats). In prior
studies, we demonstrated that HIP rats manifest cardiac
dysfunction that closely resembles, as phenotype and time
course, the heart disease in patients with T2D.34,35 Brieﬂy,
early diastolic dysfunction and mild hypertrophy, which start
in the prediabetic stage, evolve to systolic dysfunction, overt
hypertrophy, and left ventricular dilation with the advancement of T2D.
The increase in [Na+]i in HIP rat hearts (3 mmol/L) is
comparable to the [Na+]i rise reported by us11 and others12–15
in myocytes from failing hearts. In HF, elevated [Na+]i was
directly linked to a higher propensity for arrhythmias,16,49
oxidative stress17–19 and hypertrophy.50 HIP rats also
display increased arrhythmogenicity,51 oxidative stress, and
hypertrophy.34,35 Our current data suggest that high [Na+]i
may contribute to the multifactorial mechanisms through
which T2D heightens the risk of developing HF and sudden
cardiac death.
DOI: 10.1161/JAHA.115.002183

We found that the increased [Na+]i in diabetic myocytes is due
to a larger Na+ inﬂux (by 40% versus control) as opposed to
reduced Na+ extrusion via the NKA. There are multiple routes for
Na+ entry in myocytes. Quantitatively, NCX brings in the largest
amount (40% of the total Na+ inﬂux in resting rat myocytes38).
It is unlikely, however, that NCX contributes to the enhanced
Na+ entry in T2D myocytes because our previous studies
revealed reduced NCX expression (by about 20%34) and
function (measured as the rate of decline of the caffeine
induced Ca2+ transients35) in HIP rat hearts. Consequently, Na+
uptake through NCX may actually be reduced in diabetic hearts.
A pathway rarely mentioned when discussing cardiac Na+
inﬂux is SGLT, which couples ion transport to energy substrate
metabolism by taking up 2 Na+ ions together with 1 glucose
molecule. SGLT expression was initially thought to be limited to
the epithelial cells from the intestine and kidneys, but more
recent data have demonstrated that at least the SGLT1 isoform
is also present in the heart.26,27 The physiological and
pathophysiological roles of SGLT in the heart are poorly
understood. We found that SGLT-mediated Na+ and glucose
entry are negligible in myocytes from control rats, and that
implies a minor role for SGLT in myocyte Na+ and glucose
homeostasis under physiological conditions. Recent studies
revealed that the expression of SGLT1 mRNA in the heart is
increased in T2D.27 We hypothesized that SGLT is upregulated
in diabetic hearts to compensate for the reduced ability of
myocytes to take up glucose through insulin-dependent
pathways and/or as an adaptation to chronic hyperglycemia.
Indeed, external glucose modulates SGLT expression through a
glucose-sensing mechanism.26 In support of this hypothesis,
we found that the protein expression of SGLT1 is increased in
hearts from humans and rats with T2D. Obesity, in the absence
of T2D, was also associated with elevated levels of cardiac
SGLT1 in human hearts. SGLT inhibition (both pharmacological
and through omission of glucose from external solution) greatly
reduced the rate of Na+ inﬂux in myocytes from diabetic rats to a
level comparable to that measured in control myocytes. This
indicates that SGLT is the main pathway responsible for the
excess Na+ entry and thus [Na+]i elevation in T2D myocytes. The
SGLT-mediated Na+ ﬂux in our measurements is normalized to
cell volume. Because many cardiomyopathies are associated
with detubulation and thus lower membrane surface/volume
ratio, our measurement might slightly underestimate the
increase in SGLT-mediated Na+ ﬂux density (ie, normalized to
membrane area). We also found that a signiﬁcantly larger
fraction of glucose uptake is mediated by SGLT in diabetic
versus control myocytes. Together, these data indicate that
T2D triggers an increase in the activity of cardiac SGLT, which
leads to larger myocyte Na+ entry and Na+ overload.
Journal of the American Heart Association
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Recent studies point to a pathological role of SGLT
upregulation in the heart. Mice with cardiac-speciﬁc overexpression of the SGLT1 isoform develop hypertrophy and left
ventricular dysfunction.28 SGLT1 is upregulated in transgenic
mice with a mutation in the gene encoding the c2 subunit of
AMP-activated protein kinase that is known to cause a
glycogen storage cardiomyopathy (PRKAG2 cardiomyopathy)30 and mediates, at least in part, the increased cardiac
glucose uptake. Moreover, SGLT1 inhibition attenuated the
disease phenotype. SGLT activity is also needed for NADPH
activation by hyperglycemia.29 However, the mechanisms
that link SGLT function to such alterations in the structure
and function of the heart are unclear. We propose that an
increase in myocyte [Na+]i due to enhanced Na+ entry
through SGLT is a key contributor to these pathologies.
In several HF models, the increase in myocyte [Na+]i is due
to larger Na+ inﬂux mediated by Na+ channels or the Na+/H+
exchanger.11,13 The expression of the NCX, the main route for
Na+ entry, is increased in HF, which may also cooperate to
raise Na+ inﬂux. In contrast, our data show that in diabetic
hearts, the excess Na+ entry occurs mostly through SGLT.
Thus, distinct pathways are responsible for myocyte Na+
overload in T2D and HF. A previous study demonstrated that
SGLT expression is upregulated in HF,27 a result conﬁrmed by
our results in human hearts; however, no data indicated a
possible contribution of SGLT to Na+ entry in HF. This
suggests that in addition to upregulating SGLT expression,
T2D also creates a milieu that promotes activation of the
cotransporter. Our ﬁnding that SGLT-mediated Na+ inﬂux is
7 times higher in HIP versus WT myocytes, whereas SGLT
expression increases of <2-fold support this hypothesis.
Although SGLT regulation is incompletely elucidated, glucose
(via N-glycosylation),52 insulin,53 and protein kinases A and
C26,53 raise its activity by modifying either the afﬁnity for
glucose or the maximal turnover rate.
In summary, we have demonstrated that myocyte Na+–
glucose cotransport is enhanced in T2D, probably as a
maladaptation to reduced insulin-mediated glucose uptake
and chronic hyperglycemia. Elevated SGLT activity increases
Na+ inﬂux into myocytes and causes Na+ overload, which may
contribute to arrhythmogenesis and oxidative stress in
diabetic hearts. Although elevated [Na+]i and Na+ inﬂux are
also common in other pathological conditions (eg, HF), the
major underlying mechanism in diabetic heart disease is
speciﬁc to T2D.
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